Frontlight ResearchEarly access
Taking peopleNo phase
EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn
Key facts
- Who runs it
- Intressa Vascular SA
- Where
- Austria, Belgium, Bulgaria, France, Germany, Poland, Serbia, and Uzbekistan21 sites in 8 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 72 people, planned
- Started
- 30 Oct 2024
- Expected to end
- Jun 2031
- Type of study
- Interventional
- Treatments tested
- Allay Aortic Stent
- Record updated
- 16 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Have a type B aortic dissection extending to the celiac trunk or beyond
- Are eligible for thoracic endovascular treatment with stent grafts as per local guidelines, and physician's decision
- Have been elected for treatment with commercially available stent graft as per their IFU within 90 days of dissection symptoms onset
Who cannot take part
- General Exclusion Criteria:; Age < 18 years; Pregnant, breast-feeding or planning on becoming pregnant during the entire duration of the study; Unable to provide written informed consent; Unable or unwilling to comply with the requirements of the study protocol; Taking part already in an investigational device or drug study that could interfere with the outcomes being studied; Active drug addiction or known history of drug abuse within one year of treatment
- Medical Exclusion Criteria:; Aortic rupture (free or contained including haemothorax, increasing periaortic hematoma, or mediastinal hematoma); Aortic fistula; Suspicion of bowel necrosis or irreversible visceral ischemia; Stage 5 chronic kidney disease; Life expectancy of less than 2 years due to any other medical condition than the dissection to be treated; Active malignancy; Known sensitivities or allergies to the device materials (including cobalt, chromium, nickel); Known sensitivities or allergies to contrast materials that cannot be pre-medicated; Mycotic aortic aneurysm or active systemic infection that may place the patient at increased risk of endovascular infection; American Society of Anaesthesiologists (ASA) class V (moribund patient not expected to live 24 hours with or without operation); Diagnosed or suspected congenital degenerative connective tissue disease (e.g., Marfan's, Loeys-Dietz or Ehlers-Danlos syndrome); Uncorrectable coagulopathy, bleeding diathesis or refusal of blood transfusion; Any major cardiovascular or cerebrovascular ischemic event, including myocardial infarction or stroke, or treatment of such event, within 90 days prior to enrolment; Any aortic-related interventional or surgical procedure within 30 days prior to enrolment; Any planned aortic-related interventional or surgical procedure within 30 days after the study procedure
- Anatomical Exclusion Criteria:; Aneurysmal dilatation of the false lumen defined as maximum transaortic diameter >55 mm in women or >60 mm in men in the thoraco-abdominal segment or >50 mm in women or >55 mm in men in the abdominal segment, measured inner-wall to inner-wall; Inadequate proximal landing zone for the stent graft, such zone being <20 mm long; Inadequate proximal landing zone geometry for the Allay® Aortic Stent (e.g. aortic kink); Planned implantation of a stent graft with a distal diameter >38 mm or <20 mm; Aorta or iliac anatomy not allowing the advancement of the delivery system; Subject in whom the thoracic stent graft is either 1) not implanted in its intended position and/or 2) leads to any serious device complication, and/or who has 3) persistent static obstruction of the visceral or both renal arteries, prior to Allay® Aortic Stent implantation, will not be implanted with the Allay® Aortic Stent and will be withdrawn from the study
This trial has no sites in United States.
It has sites in 8 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial is a prospective, multicenter, open label study designed to evaluate the effectiveness and the safety of the Allay® Aortic Stent as adjunctive endovascular treatment of Type B aortic dissection in patients eligible for thoracic endovascular aortic repair with stent grafts.
The group in the trial
- Allay Aortic StentTreatment being tested
A covered thoracic stent graft is first deployed in supraceliac position as per standard of care then followed by the implantation of the Allay® Aortic Stent deployed from within the stent graft, extending below the celiac trunk to the end of the dissected aorta, typically the aortoiliac bifurcation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Clinical Study to Evaluate the Effectiveness and Safety of the Allay® Aortic Stent as Adjunctive Endovascular Treatment of Type B Aortic Dissection in Patients Eligible for Thoracic Endovascular Repair With Stent Grafts
- Record updated
- 16 September 2026